SAN DIEGO , Aug. 21, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the promotion of Karen A. Sztraicher to Executive Vice President, Asset Management and Jonathan P. Klassen to Senior Vice President and General Counsel.
Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty, remarked, "I am very pleased to announce the promotions of Karen and Jon, both of whom have a strong track record of success and have been an integral part of our growth at BioMed Realty since our inception. Karen's wealth of experience, tremendous leadership skills and determination have helped to define and shape our premier operating platform and world-class team of professionals."
Ms. Sztraicher's distinguished career includes extensive experience in asset management and real estate accounting and finance. During her tenure at BioMed Realty, she has served in a range of capacities with a wide scope of responsibilities, most recently overseeing asset management and real estate operations as Senior Vice President, Asset Management. Prior to joining Bernardo Property Advisors, the predecessor to BioMed Realty, Ms. Sztraicher held a variety of senior positions in real estate accounting, finance and asset management at GMS Realty, LLC, CB Richard Ellis and Donahue Schriber. She became a certified public accountant in 1988 and received her Bachelors of Science Degree from Cal State Polytechnic University, Pomona.
Commenting on Jon Klassen's promotion, Gary A. Kreitzer, Executive Vice President and Director of BioMed Realty, noted, "Throughout the past eight years, Jon has been instrumental in developing and managing our corporate legal team to support our sustained, long-term growth. Most recently serving as our company's Assistant General Counsel and Secretary, Jon has led successful cross-functional initiatives to enhance our insurance and risk management, human resources and communications functions and further strengthen our organization's operating capabilities as a whole. His broad, deep knowledge and experience in applying legal principles and sound business judgment to our business provide tremendous value to the company." Mr. Kreitzer will continue to serve as a senior executive officer and as a member of the Board of Directors for BioMed Realty.Mr. Klassen joined the company just after its initial public offering in 2004 and has served as a Vice President since 2006, as the company's Secretary since 2008 and as the company's Assistant General Counsel since 2010. Prior to joining BioMed Realty in 2004, Mr. Klassen was with Latham & Watkins LLP, where he focused on corporate finance transactions, mergers and acquisitions and general company representation. Mr. Klassen received his Juris Doctor Degree from the University of Pennsylvania and is a member of the California State Bar and San Diego County Bar Association. About BioMed Realty Trust BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.1 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, San Diego, Maryland, New York/ New Jersey, Pennsylvania and Seattle, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE BioMed Realty Trust, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV